Inspire Medical Systems, Inc. INSP
Inspire's surgical sleep-apnea implant is too invasive to ever scale — VA sales prove patients refuse it for free, while insiders have dumped $340M cashing out a fictional $10bn TAM story.
Thesis
Wolfpack is short Inspire Medical Systems (INSP), arguing the company's hypoglossal-nerve stimulator for obstructive sleep apnea is far too invasive — three 2.5-inch incisions, 7-10 year battery-replacement surgeries, MRI/pacemaker/electronics restrictions, and an 85% adverse-event rate in the STAR trial — to ever achieve management's promoted $10bn TAM. Real-world data confirms the rejection: only 387 of 9 million eligible U.S. veterans have opted in since 2014, with VA sales peaking at 150 units in 2018 and falling to 110 in 2019. Insiders, including CEO Tim Herbert and OrbiMed director Chau Khuong, have sold over $340M in stock — nearly 3x cumulative revenue — without a single open-market purchase. Wolfpack's independent Frost & Sullivan data pegs realistic TAM at ~104,125 units, ~50x below management's claim, making sustained losses and a collapsing growth narrative inevitable.
SCQA
Inspire Medical Systems sells a surgically implanted hypoglossal-nerve stimulator for obstructive sleep apnea, marketed as a 'minimally invasive' alternative to CPAP within a $10bn purported U.S. opportunity.
The device requires three incisions, periodic battery-replacement surgery, has an 85% adverse-event rate in trials, and patients refuse it even for free — only 387 of 9M eligible VA veterans opted in since 2014.
Short INSP: discount management's self-serving 'company estimate' TAM, follow insider selling (>$340M cashed out, zero buys), and use real Frost & Sullivan data showing TAM is <2% of claimed.
Wolfpack's reality-adjusted TAM of ~104,125 units versus the claimed 500,000 implies a ~50x downward revision; with a -42.5% operating margin and worsening unit economics, INSP's growth thesis collapses.
The three reasons
- 1
Inspire's surgical OSA implant is invasive and intolerable — patients reject it even when free
- 2
Insiders cashed out >$340M (3x total revenue since IPO) with zero open-market buys
- 3
Management's $10bn TAM is exaggerated ~50x; real TAM is <2% of that claim
Primary demands
- Investors should short INSP and avoid the stock
- Focus on management's actions (insider selling), not their words
- Disregard management's $10bn TAM claim as fictional
KPIs cited
Pattern membership
Precedents cited
- Lobotomies for migraines in the 1950s (analogy for invasive procedure rejection)
Composition what's on the 57 slides
Slide gallery ·
Notes
Classic short-seller research note format: Word-document layout with embedded screenshots, charts, and tables rather than slide-deck design. Strong narrative craft — uses 'Inspire's promotions vs. Reality' juxtaposition on cover (anatomical diagram vs. graphic post-op patient photo), patient testimonials ('Patient A', 'Patient B'), CEO quote-mining from SVB Leerlink and RBC conferences, and a clean methodology comparison (Inspire's TAM funnel vs. Wolfpack's reality-adjusted version on pp. 14-15). Pre-emptive 'this is not a COVID thesis' framing on p. 3. Heavy footnoting with hyperlinks to FDA/ClinicalTrials.gov sources. Author byline is the firm itself ('Wolfpack'), no individual signature. Closing slides are pure financial disclaimer boilerplate. Visual production is utilitarian — institutional but not editorial-grade.